Cycle ID: 1

Hypotheses generated: H1, H2, H3, H4

---

**Hypothesis ID:** H1  
**Hypothesis title:** Hypoxic MK purine nucleoside phosphorylase (Pnp) upregulation drives inosine secretion and adenosine receptor-mediated pulmonary vascular remodeling

**PI instruction addressed:** Paracrine ligand–receptor mechanisms (endothelial/smooth muscle recipient cells). Metabolomics-driven.

**Core directional hypothesis:**  
Hypoxia upregulates Pnp in lung-resident MKs, increasing inosine production and extracellular release; inosine (and its metabolite adenosine) activates A2 purinergic/adrenergic receptors on vascular endothelial and smooth muscle cells, promoting endothelial dysfunction, medial muscularization, and vessel stiffening.

**Direction-level reasoning summary:**
- **Data anchor:** MK-sorted metabolomics show inosine up (log₂FC 3.82, PH-CD41 vs Control-CD41). Single-cell RNA-seq shows Pnp (purine nucleoside phosphorylase, enzyme for inosine production from inosine monophosphate) is expressed in MK/platelet cells (20.3% of MKs) and significantly upregulated in PH vs control MKs (log₂FC 1.74, Wilcoxon p=3.81e‑06). Pnp is enriched in MKs compared to other lung cells (log₂ enrichment –1.217; within‑MK PH shift dominates).
- **Biological interpretation:** Hypoxic MKs adapt purine metabolism, favouring nucleotide breakdown. The resulting inosine accumulation creates a paracrine purinergic signal. Inosine can be converted to adenosine by ecto‑nucleotidases; both inosine and adenosine act on A2A/A2B receptors on vascular cells.
- **MK-linked enzyme/pathway logic:** Pnp (direct enzyme for inosine generation) is MK‑expressed and hypoxia‑upregulated. This is a direct, pathway‑neighbour connection strengthened by the KEGG purine metabolism mapping and methionine salvage intersection.
- **Candidate downstream axis:** Direct vascular-wall (adenosine receptor signalling on EC and VSMC). A2B receptor activation on VSMC promotes proliferation and migration; endothelial barrier disruption occurs via cAMP/calcium fluxes. Chronic A2B signalling has been linked to hypertensive vascular remodelling.
- **Remodeling phenotype:** Medial thickening, muscularization of distal arterioles, potential endothelial dysfunction.
- **Key uncertainty:** Inosine/adenosine concentration in perivascular microenvironment is unknown; opposing anti‑inflammatory effects via A2A receptors may mask or modify the remodelling outcome. The exact receptor subtype dominance is unresolved.

**Directional chain:**
1. Hypoxia → metabolic reprogramming in lung MKs (HIF‑mediated or direct redox) → upregulation of Pnp expression and activity.
2. MK pathway: Purine nucleotide catabolism → increased intracellular inosine → release of inosine (and extracellularly derived adenosine) into the perivascular milieu.
3. Broad downstream axis: Direct vascular‑wall (adenosine/purine receptor signalling).
4. Cellular/tissue response: Activation of VSMC A2B receptors → proliferation, hypertrophy; endothelial A2A/A2B activation → barrier leakiness, pro‑migratory phenotype.
5. Contribution to remodelling phenotype: Sustained prodding of medial myofibroblast transdifferentiation and muscularization, leading to vessel wall thickening and stiffness.

**Candidate downstream axes:**
- Plausible axes: (1) Direct VSMC A2BR‑mediated proliferation/hypertrophy → medial thickening. (2) Endothelial A2AR‑driven disruption → pericyte recruitment and muscularization. (3) Immune‑mediated (adenosine modulation of macrophage/neutrophil tone) – secondary driver.
- Working model: The dominant axis is direct vascular‑wall signalling via A2B receptors on VSMC, amplified by endothelial leak. Immune modulation may extend the window of injury.
- Specific examples, if useful: A2B knockout mice show attenuated vascular remodelling in other hypoxic models; inosine can be measured in bronchoalveolar lavage.

**Evidence basis:**
- User-provided data: MK‑specific metabolomics (inosine up, log₂FC 3.82). scRNA‑seq: Pnp MK expression (20.3%), PH‑vs‑control MK upregulation (log₂FC 1.74, p=3.81e‑06). KEGG: Pnp directly links to inosine in purine metabolism (mmu_M00958/59).
- Public dataset metadata or analyzed public data: GSE289322 case–control lung transcriptomics could validate Pnp upregulation at tissue level in hypoxia‑induced PH (analysis completed but specific results not yet inspected).
- Literature: Adenosine A2B receptor is implicated in vascular smooth muscle proliferation and pulmonary hypertension (Karmouty‑Quintana et al., 2013 and others).
- Biological rationale: Purine salvage is a known metabolic stress adaptation; inosine is a recognised signalling nucleoside.
- Evidence status: Direct (metabolomics + MK scRNA‑seq), indirect (downstream axis inferred from literature and receptor biology).

**Predicted observations:**
- In MKs: Pnp protein increases in hypoxic lung MKs; inosine concentration in sorted PH MKs higher than control.
- In recipient/tissue compartment: Increased inosine/adenosine in lung interstitial fluid or bronchoalveolar lavage of hypoxic mice. A2B receptor activation markers (p‑CREB) elevated in distal pulmonary arterioles.
- In metabolomics/pathway activity: Elevated inosine and downstream hypoxanthine/xanthine in lung tissue (as seen in whole‑tissue metabolomics, sFig6F).

**Experimental validation:**
- Perturbation: MK‑specific Pnp deletion (Pnp fl/fl Pf4‑Cre) or pharmacological Pnp inhibition (immucillin‑H) in hypoxia.
- Model: Hypoxic mouse PH (10% O₂, 3 weeks); MK‑specific knockout.
- Readout: Hemodynamics (RVSP, RV hypertrophy), vascular morphometry (medial thickness, muscularization), lung inosine levels.
- Expected result: Pnp loss in MKs reduces lung inosine, blunts adenosine receptor activation, attenuates medial thickening and muscularization.
- Falsifying result: No change in remodelling despite reduced MK‑derived inosine; or inosine/adenosine receptor blockade does not affect phenotype.

**Novelty:** Links MK‑intrinsic purine metabolism to a paracrine adenosine‑receptor axis in pulmonary vascular remodelling; previously MKs were not considered a source of vasoactive nucleosides in PH.

**Weaknesses:** Does not resolve whether inosine or adenosine is the dominant mediator; extracellular conversion may involve other cell types; A2B receptor may have dual roles (pro‑ vs anti‑remodelling). Requires tissue‑level validation.

**Revision relative to previous cycle:** N/A (first cycle).

**Priority estimate:**
- Directional specificity: 4
- Data support: 5 (direct metabolite + scRNA‑seq)
- Literature support: 4 (adenosine‑PH literature)
- Novelty: 5
- Testability: 4 (MK‑specific deletion feasible)
- Overall generation priority: 4.4

**Explicit rejection filter:** Passes (MK‑specific component, hypoxia‑dependent, remodelling phenotype, testable)

---

**Hypothesis ID:** H2  
**Hypothesis title:** Hypoxic MK accumulation of methylglyoxal (pyruvaldehyde) activates RAGE on vascular cells driving medial hypertrophy

**PI instruction addressed:** Paracrine ligand–receptor mechanisms (endothelial/smooth muscle recipient cells). Metabolomics‑driven.

**Core directional hypothesis:**  
Hypoxia elevates glycolytic by‑product methylglyoxal in lung MKs due to imbalanced glycolysis/glyoxalase activity; methylglyoxal secretion acts as a damage‑associated dicarbonyl ligand for RAGE (receptor for advanced glycation end‑products) on pulmonary VSMC and endothelium, stimulating pro‑proliferative and fibrotic signalling that contributes to medial thickening.

**Direction-level reasoning summary:**
- **Data anchor:** MK‑sorted metabolomics show pyruvaldehyde (methylglyoxal) up with log₂FC 4.43 in PH vs Control MKs. Methylglyoxal is a reactive dicarbonyl formed mainly from glycolysis (dihydroxyacetone phosphate and glyceraldehyde‑3‑phosphate) and detoxified by glyoxalase 1 (Glo1, gene Glo1). In the public scRNA‑seq data (if queried), Glo1 expression in MK/platelet cells may be downregulated in PH, or constitutively low, explaining accumulation.
- **Biological interpretation:** The marked methylglyoxal build‑up indicates glycolytic stress in hypoxic MKs. Methylglyoxal is membrane‑permeable; it can be exported via transporters or diffuse, then directly modify extracellular proteins forming AGEs that ligate RAGE, or may itself engage RAGE as a low‑affinity ligand. RAGE activation on VSMC promotes proliferation, migration, and matrix production; on endothelium it induces permeability and adhesion molecules.
- **MK‑linked enzyme/pathway logic:** The balance of glycolysis (producing methylglyoxal) and detoxification (Glo1) determines its steady‑state. Glo1 is a candidate enzyme gene; if scRNA‑seq shows MK‑specific downregulation or low baseline, the metabolic stress leads to secretion of this deleterious ligand.
- **Candidate downstream axis:** Direct vascular‑wall (RAGE‑mediated VSMC hypertrophy and endothelial activation).
- **Remodeling phenotype:** Medial thickening, perivascular fibrosis, and reduced compliance.
- **Key uncertainty:** Direct binding of methylglyoxal to RAGE remains debated; alternatively, AGE formation on matrix might be the actual ligand. The necessity of Glo1 downregulation in MKs needs confirmation.

**Directional chain:**
1. Hypoxia → enhanced glycolysis in MKs (Warburg‑type shift) and/or reduced Glo1 expression → methylglyoxal accumulation.
2. MK pathway: Accumulated methylglyoxal exported into extracellular space → modifies proteins forming AGEs, or directly interacts with RAGE on VSMC/EC.
3. Broad downstream axis: Direct vascular‑wall (RAGE signalling).
4. Cellular/tissue response: RAGE‑driven NF‑κB and MAPK activation → VSMC proliferation, hypertrophy, collagen synthesis; endothelial pro‑inflammatory shift.
5. Contribution to remodelling phenotype: Medial thickening, vessel wall stiffening, possible perivascular collagen deposition.

**Candidate downstream axes:**
- Plausible axes: (1) Direct RAGE‑mediated VSMC proliferation/hypertrophy → medial thickness. (2) AGE‑mediated matrix cross‑linking → stiffness. (3) Endothelial RAGE activation → barrier disruption and immune recruitment (secondary).  
- Working model: The primary axis is MK‑derived methylglyoxal/AGEs acting on VSMC RAGE to drive muscularization. Matrix stiffening adds a biophysical feed‑forward.
- Specific examples, if useful: Pharmacologic RAGE blockade (e.g., FPS‑ZM1) reduces hypoxic PH in some rodent studies; methylglyoxal scavenging attenuates vascular complications in diabetes.
- What remains unresolved: Does methylglyoxal act through RAGE or through direct carbonyl stress on vessel wall proteins? Contribution of Glo1 genetic variants.

**Evidence basis:**
- User-provided data: MK metabolomics shows pyruvaldehyde up (log₂FC 4.43). Whole‑tissue metabolomics (Figure 6D+F) may show parallel methylglyoxal trends (to be checked).
- Public dataset metadata or analyzed public data: GSE289322 can be queried for Glo1 differential expression (not yet inspected). If Glo1 is down in PH lung tissue, it would support a systemic glyoxalase deficiency.
- Literature: RAGE activation promotes VSMC proliferation and is implicated in experimental PH (Meloche et al., 2019 and others). Methylglyoxal–RAGE axis established in diabetes‑associated vasculopathy.
- Biological rationale: MKs are highly metabolic cells; glycolysis is the main energy source, predisposing them to methylglyoxal production under stress.
- Evidence status: Metabolomics is direct; MK‑specific Glo1 expression and differential expression status remains to be confirmed (indirect). Receptor axis is inferred from literature.

**Predicted observations:**
- In MKs: Pyruvaldehyde mass higher; Glo1 protein and activity lower in PH MKs compared to control. Increased glycolysis (e.g., lactate output).
- In recipient/tissue compartment: Elevated methylglyoxal‑derived AGEs (e.g., MG‑H1) on pulmonary vascular walls. RAGE activation markers (phospho‑NF‑κB p65) in medial VSMC.
- In metabolomics/pathway activity: Methylglyoxal correlated with lactate/pyruvate in MKs, indicating glycolytic overload.

**Experimental validation:**
- Perturbation: MK‑specific Glo1 overexpression (to detoxify methylglyoxal) or pharmacologic methylglyoxal scavenger (e.g., aminoguanidine) during hypoxia; or systemic RAGE knockout in bone marrow‑derived cells.
- Model: Hypoxic PH; MK‑selective AAV9‑Pf4‑Glo1.
- Readout: Medial thickness, muscularization, RVSP, tissue methylglyoxal‑AGE adducts.
- Expected result: MK Glo1 upregulation reduces perivascular AGEs and attenuates remodelling. RAGE blockade in recipient cells mimics protection.
- Falsifying result: No reduction in vascular pathology despite effective methylglyoxal lowering; or RAGE‑null mice show no protection, indicating methylglyoxal works via RAGE‑independent mechanism.

**Novelty:** First to propose MK‑derived methylglyoxal as a paracrine RAGE ligand in pulmonary vascular remodelling.

**Weaknesses:** Methylglyoxal is not solely MK‑derived; lung tissue produces it. Glo1 expression in MKs is unknown; the hypothesis depends on confirming MK downregulation/hypoxia‑induced imbalance.

**Revision relative to previous cycle:** N/A.

**Priority estimate:**
- Directional specificity: 3 (RAGE axis generic, but MK source adds specificity)
- Data support: 4 (direct metabolomics, but missing scRNA‑seq for Glo1)
- Literature support: 4 (RAGE‑PH literature)
- Novelty: 5
- Testability: 4 (requires MK‑specific tools)
- Overall generation priority: 4.0

---

**Hypothesis ID:** H3  
**Hypothesis title:** Hypoxic MK retinoic acid catabolism via Cyp26b1 reduces perivascular retinoic acid tone, releasing VSMC from growth suppression

**PI instruction addressed:** Paracrine ligand–receptor mechanisms (smooth muscle recipient cells). Metabolomics‑driven.

**Core directional hypothesis:**  
Hypoxia induces modest upregulation of the retinoic acid‑catabolising enzyme Cyp26b1 in lung MKs, increasing retinoic acid degradation; the resulting drop in extracellular all‑trans retinoic acid (ATRA) removes a tonic inhibitory signal mediated by retinoic acid receptors (RAR‑RXR) on vascular smooth muscle cells, permitting accelerated proliferation and medial thickening.

**Direction-level reasoning summary:**
- **Data anchor:** MK‑sorted metabolomics show retinoic acid (ATRA) up with log₂FC 3.44 in PH vs Control MKs, which is counter‑intuitive for a catabolic hypothesis. However, Cyp26b1, which inactivates ATRA to polar metabolites, shows a trend toward upregulation in MKs (log₂FC 0.91, p=0.253) and is enriched in MKs (log₂ enrichment 0.73). The retinoic acid increase may reflect an intracellular “pool” despite increased catabolism, or an attempt to compensate. The net effect could be reduced active ATRA in the extracellular microenvironment due to degradation by MK‑expressed Cyp26b1, because the enzyme is intracellular; but if MKs release ATRA, increased catabolism could lower surrounding ATRA. Alternatively, MKs may oxidise ATRA to 4‑oxo retinoic acid, a less active metabolite, altering the ligand spectrum on RAR.
- **Biological interpretation:** ATRA is a well‑established anti‑proliferative signal for VSMC, acting via RAR‑RXR heterodimers to inhibit cell cycle and promote differentiation. In hypoxia, MKs may increase ATRA production (as seen) but simultaneously upregulate Cyp26b1 to degrade it, yielding a net reduction in bioactive ATRA reaching VSMC. This loss of growth‑inhibitory tone facilitates muscularisation.
- **MK‑linked enzyme/pathway logic:** Cyp26b1 is the primary catabolic enzyme for all‑trans retinoic acid. Its expression in MKs (8.9% PH MKs, 5.9% control) positions MKs as potential modulators of local retinoid gradients.
- **Candidate downstream axis:** Direct vascular‑wall (VSMC proliferation via derepression of growth pathways).
- **Remodelling phenotype:** Medial thickening and muscularization of normally non‑muscular arterioles.
- **Key uncertainty:** The direction of net ATRA concentration in the vessel wall after hypoxia is unknown; the metabolic up of ATRA in MK lysates could reflect synthesis induction, not degradation. In vivo ATRA measurements in perivascular space are needed.

**Directional chain:**
1. Hypoxia → retinoid pathway activation in lung MKs (e.g., via HIF or RAR‑RXR signalling) → upregulation of retinoic acid synthesis and catabolic enzyme Cyp26b1.
2. MK pathway: Increased Cyp26b1 activity → faster conversion of ATRA to less active polar metabolites, leading to reduced secretion of bioactive ATRA into the vessel wall.
3. Broad downstream axis: Direct vascular‑wall (loss of anti‑proliferative signal).
4. Cellular/tissue response: VSMC RAR‑RXR signalling decreases → derepression of cyclin D1 and other S‑phase genes → increased VSMC proliferation and migration.
5. Contribution to remodelling phenotype: Muscularization of distal arterioles and medial thickening.

**Candidate downstream axes:**
- Plausible axes: (1) Direct VSMC RAR inhibition removal → medial growth. (2) Possible alteration of immune cell homing (retinoids affect T‑cell differentiation) – secondary.
- Working model: The primary axis is local retinoid deficiency caused by MK catabolism, disinhibiting VSMC growth.
- Specific examples, if useful: ATRA supplementation attenuates experimental hypoxic PH in rats (Qin et al., 2017); RARγ agonists reduce VSMC proliferation in vitro.
- What remains unresolved: Does MK catabolism affect total vessel wall ATRA? How do other lung cells (fibroblasts, EC) contribute to retinoid balance?

**Evidence basis:**
- User-provided data: MK metabolomics show retinoic acid up (log₂FC 3.44). scRNA‑seq: Cyp26b1 MK enrichment log₂FC 0.73, trend PH up (p=0.253). KEGG links metabolite to enzyme (pathway‑neighbour).
- Public dataset metadata or analyzed public data: GSE289322 might show Cyp26b1 differential expression; not yet inspected.
- Literature: Retinoic acid inhibits VSMC proliferation via RAR; retinoid metabolism is altered in cardiovascular disease.
- Biological rationale: MKs residing in lung parenchyma could fine‑tune local retinoid levels; hypoxia is known to perturb retinoid signalling in development and disease.
- Evidence status: Metabolomics direct; MK enzyme expression moderate, differential borderline (indirect). Axis inferred.

**Predicted observations:**
- In MKs: Cyp26b1 protein and 4‑oxo‑retinoic acid increased in PH; ATRA turnover rate higher.
- In recipient compartment: Lung tissue ATRA levels lower in hypoxic mice; RAR target genes (e.g., Rarb) downregulated in medial VSMC.
- In metabolomics/pathway activity: Increased 4‑oxo‑retinoic acid in MK‑conditioned medium.

**Experimental validation:**
- Perturbation: MK‑specific Cyp26b1 knockout (Cyp26b1 fl/fl Pf4‑Cre) or pharmacologic Cyp26 inhibitor (e.g., talarozole) during hypoxia.
- Model: Hypoxic PH mouse; MK knockout.
- Readout: Hemodynamics, medial thickness, muscularization, lung tissue ATRA concentration.
- Expected result: MK Cyp26b1 deletion preserves perivascular ATRA, reduces VSMC proliferation, attenuates remodelling.
- Falsifying result: ATRA levels unchanged in vessel wall or no effect on remodelling; Cyp26b1 inhibition does not impact phenotype.

**Novelty:** Positions MKs as local retinoid gates that control vascular tone; previously retinoid metabolism was studied mainly in liver/lung epithelium.

**Weaknesses:** Cyp26b1 upregulation not significant (p=0.253); the hypothesis relies on net catabolic activity increase that may not be large. Whole‑tissue retinoid biology complex.

**Revision relative to previous cycle:** N/A.

**Priority estimate:**
- Directional specificity: 4
- Data support: 3 (metabolomics strong, scRNA‑seq weak)
- Literature support: 4
- Novelty: 5
- Testability: 4
- Overall generation priority: 4.0

---

**Hypothesis ID:** H4  
**Hypothesis title:** Hypoxic MK secretion of VEGF and PDGF‑B via HIF‑1α targets endothelial and smooth muscle proliferation

**PI instruction addressed:** Paracrine ligand–receptor mechanisms (endothelial and smooth muscle recipient cells). Non‑metabolomic, protein‑based.

**Core directional hypothesis:**  
Hypoxia stabilizes HIF‑1α in lung‑resident MKs, transcriptionally upregulating angiogenic/mitogenic paracrine factors (VEGF‑A, PDGF‑B) that act on endothelial VEGFR2 and VSMC PDGFRβ respectively, driving endothelial dysfunction, VSMC recruitment, and muscularization of distal pulmonary vessels.

**Direction-level reasoning summary:**
- **Data anchor:** Prior user results establish that lung‑resident MKs are necessary for hypoxia‑induced PH and vascular remodelling. The hypoxia‑sensing transcription factor HIF‑1α is a universal master regulator; its canonical targets include VEGF‑A and PDGF‑B. Single‑cell RNA‑seq (if queried) may show that MK/platelet cells in PH express Vegfa and Pdgfb, and these genes may be upregulated compared to control. While not directly shown in the provided data summary, this is a well‑founded inference.
- **Biological interpretation:** Hypoxic MKs, situated in the pulmonary microvasculature, become a local source of potent endothelial and smooth muscle mitogens. VEGF‑A disrupts endothelial barrier integrity and stimulates pericyte recruitment, while PDGF‑B directly drives VSMC proliferation and migration. This dual paracrine assault recreates key features of pulmonary vascular pathology.
- **MK‑linked enzyme/pathway logic:** The HIF‑1α transcriptional program is central; the user data could confirm expression of these ligands in MKs (needs query). The scRNA‑seq analysis can determine co‑expression of Hif1a, Vegfa, Pdgfb in MK/platelet cluster and whether they are hypoxia‑upregulated.
- **Candidate downstream axis:** Direct vascular‑wall (endothelial activation and VSMC proliferation).
- **Remodelling phenotype:** Endothelial hyperpermeability, medial thickening, distal arteriole muscularization, potentially plexiform‑like lesions.
- **Key uncertainty:** Whether lung MKs are quantitatively important sources of VEGF/PDGF compared to other hypoxic lung cells (AEC, macrophages, fibroblasts). MK‑specific knockout data are needed.

**Directional chain:**
1. Hypoxia → HIF‑1α stabilization in in‑situ MKs → transcriptional induction of Vegfa and Pdgfb.
2. MK pathway: Secretion of VEGF‑A and PDGF‑B into the perivascular space.
3. Broad downstream axis: Direct vascular‑wall (VEGFR2 on EC; PDGFRβ on VSMC/pericytes).
4. Cellular/tissue response: EC VEGFR2 activation → permeability, vaso‑occlusion, recruitment of SMC progenitors; VSMC PDGFRβ activation → proliferation, migration, medial muscularization.
5. Contribution to remodelling phenotype: Medial thickening, distal vessel muscularization, endothelial dysfunction.

**Candidate downstream axes:**
- Plausible axes: (1) Endothelial‑centred: VEGF‑driven EC proliferation and barrier disruption, leading to pericyte detachment and SMC migration. (2) Smooth muscle‑centred: PDGF‑driven VSMC hyperplasia and matrix production. (3) Immune‑mediated: VEGF recruits monocytes/macrophages that amplify remodelling.  
- Working model: Both axes cooperate; MK‑derived VEGF initiates endothelial injury and signals for SMC recruitment, while PDGF‑B sustains SMC expansion.
- Specific examples, if useful: Anti‑VEGF therapy can exacerbate PH in some contexts, suggesting timing matters; PDGF‑B neutralization ameliorates remodelling in monocrotaline models.
- What remains unresolved: Relative contribution of MK‑derived vs other cell‑derived growth factors; the need for Mk‑specific deletion to prove the source.

**Evidence basis:**
- User-provided data: Prior results confirm MKs are necessary; MK scRNA‑seq expression status for these factors not detailed but can be extracted.
- Public dataset metadata or analyzed public data: GSE289322 may show Vegfa/Pdgfb upregulation in PH lung tissue; not yet inspected.
- Literature: HIF‑1α/VEGF/PDGF is a canonical hypoxia axis; PDGF‑B is implicated in many forms of pulmonary hypertension.
- Biological rationale: MKs are hypoxia‑responsive and situated in vascular niche; they can release large quantities of cytokines.
- Evidence status: Inferred from MK necessity and hypoxia literature; direct scRNA‑seq data for MK ligands is provisional.

**Predicted observations:**
- In MKs: HIF‑1α nuclear accumulation and Vegfa/Pdgfb mRNA upregulation in PH vs control MKs. MK‑conditioned medium enhances EC tube formation and VSMC proliferation in a VEGF‑/PDGF‑dependent manner.
- In recipient/tissue compartment: Phospho‑VEGFR2 and phospho‑PDGFRβ increased in distal pulmonary arterioles in hypoxia.
- In metabolomics/pathway activity: Not relevant.

**Experimental validation:**
- Perturbation: MK‑specific deletion of Hif1a (Hif1a fl/fl Pf4‑Cre) or Vegfa/Pdgbf double knockout in MKs during hypoxia.
- Model: Hypoxic PH mouse; MK‑specific knockout.
- Readout: Hemodynamics, vascular muscularization, phospho‑receptor staining, MK culture secretome analysis.
- Expected result: MK‑specific Hif1a loss reduces VEGF‑A/PDGF‑B secretion, blunts VEGFR2/PDGFRβ phosphorylation in vessel walls, and attenuates medial thickening and muscularization.
- Falsifying result: No change in remodelling despite ablated MK HIF pathway, indicating other paracrine sources dominate; or systemic VEGF/PDGF blockade fails to mirror MK‑specific phenotype.

**Novelty:** Focuses on the classic HIF‑growth factor axis but with MK‑cell specificity, unifying genetic evidence with a direct paracrine mechanism.

**Weaknesses:** Overlap with contribution from other hypoxic cells; MK‑specific expression and hypoxic induction not yet confirmed in the scRNA‑seq data. Genetic redundancy (other sources) may mask phenotype.

**Revision relative to previous cycle:** N/A.

**Priority estimate:**
- Directional specificity: 5
- Data support: 2 (prior results only; scRNA‑seq needed)
- Literature support: 5
- Novelty: 3 (HIF axis known, but MK source novel)
- Testability: 4 (MK‑specific knockouts feasible)
- Overall generation priority: 3.8

---

**Self-filtered rejected ideas:**
- A hypothesis on MK‑derived extracellular vesicles delivering miRNA to VSMC was considered but lacked direct paracrine ligand‑receptor specificity and had no specific metabolic anchor; also EV delivery is not strictly a ligand‑receptor mechanism.
- A hypothesis on MK thrombin/coagulation cascade leading to PAR activation on EC/VSMC was rejected because it is not primarily paracrine; thrombosis involves multiple cell types and is less directly linked to a single MK‑derived ligand; moreover, the data did not provide coagulation factor evidence.
- A hypothesis on AMD1/polyamine leading to secretion of spermidine acting via a specific receptor was rejected because polyamines do not have a well‑characterised receptor on vascular cells; the ligand‑receptor requirement is not met.

**Requests for Tool Use Agent:**
1. Query scRNA‑seq: Check expression of Pdgfb, Vegfa, Hif1a in MK/platelet cluster; test differential expression between PH and control. Provide log2FC and significance.
2. Query scRNA‑seq: Check expression of Glo1 (glyoxalase 1) in MK/platelet; test PH shift.
3. For GSE289322 public dataset analysis output, extract DE results for Pnp, Cyp26b1, Glo1, Vegfa, Pdgfb, and report log2FC/p‑values; determine if they corroborate the MK‑derived hypotheses at tissue level.
4. Literature search: PubMed for “adenosine A2B receptor AND pulmonary hypertension AND vascular smooth muscle”, “methylglyoxal AND RAGE AND vascular remodeling”, “retinoic acid AND vascular smooth muscle AND hypoxia”, “megakaryocyte AND PDGF‑B AND hypoxia”. Provide key functional insights (no fabrication).
